Yuhan

Yuhan EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Yuhan (000100.KS) as of Nov 2, 2026 is 229.91 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 95.64 B KRW — a change of 140.39% (higher).

EBITDA

229.91 BKRW

YoY

140.39%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Yuhan is 2025 229.91 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Yuhan was 2024 95.64 B KRW. It decreases by 140.39% higher compared to the previous year.

The Yuhan EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
58.80 B KRW
Jan 1, 2019
25.15 B KRW
Jan 1, 2020
98.12 B KRW
Jan 1, 2021
62.15 B KRW
Jan 1, 2022
45.34 B KRW
Jan 1, 2023
72.41 B KRW
Jan 1, 2024
95.64 B KRW
Jan 1, 2025
229.91 B KRW
The Yuhan EBITDA history
YEAREBITDAYoY
229.91 BKRW+140.39%
95.64 BKRW+32.07%
72.41 BKRW+59.73%
45.34 BKRW-27.06%
62.15 BKRW-36.66%
98.12 BKRW+290.10%
25.15 BKRW-57.22%
58.80 BKRW-37.49%
94.06 BKRW-7.72%
101.94 BKRW+15.21%
88.48 BKRW+16.02%
76.26 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yuhan Stock analysis

What does Yuhan do? The Yuhan Corporation is a South Korean conglomerate that was founded on September 1, 1926, under the name "Chosun Pharmaceutical Company". The company is headquartered in Seoul and employs more than 5,000 people worldwide. History: The Yuhan Corporation started as a small company with a single product, a fish oil-based ointment called "Yuksundo". The company worked hard to improve its products and expand its market, eventually expanding into other business areas such as the production of antibiotics and diabetes treatments. In the early 1950s, the company also ventured into the research and development of other pharmaceuticals. In 1962, Yuhan became a publicly traded company and received a variety of awards in the following years, including several Korean Industrial Awards. Since its inception, the company has remained committed to improving people's lives through innovation and science. Business model: The Yuhan Corporation is a pharmaceutical company that focuses on the development, manufacturing, and marketing of drugs and other health products. The company also makes investments in innovative technologies and healthcare startups. Over the years, Yuhan has expanded its business through partnerships with other companies and acquisitions of companies such as LGL Holdings and SillaJen Inc. The company also engages in international business relations, such as selling its products and medications in other countries. Divisions: The Yuhan Corporation has four main business divisions: Medical Research and Development, Drug Manufacturing, Biotechnology Product Development, and Health Product Production. The first division is coordinated by Yuhan Research & Development Co. Ltd, while drug manufacturing is done by Yuhan Manufacturing Co. Ltd. Biotechnology is done by Yuhan Biomedical Research Institute, and the health product segment is handled by Yuhan Healthcare. Products: Yuhan's products are diverse and include a wide range of drugs and health products. The company is involved in the production of antibiotics, analgesics, vein treatment agents, diabetes medications, cardiovascular drugs, and other pharmaceutical products. Other products also include cosmetics, oral care products, and dermatology drugs. Some of Yuhan's well-known products include the antibiotic Ceclor, a medication for the treatment of diabetes and metabolic disorders, as well as apple-based cosmetic products. All Yuhan products are manufactured according to strict quality standards and are known for their effectiveness and safety. Conclusion: The Yuhan Corporation has evolved into a diverse and innovative company focused on the production of drugs and health products. The company has a long history with many successes and has established itself as one of the major forces in the South Korean economy over the past decades. Yuhan's mission to create better healthcare remains as relevant today as it was at the time of its founding. Yuhan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yuhan stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Yuhan is 229.91 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Yuhan changed from 95.64 B KRW to 229.91 B KRW, representing a 140.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Yuhan since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Yuhan historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Yuhan

All Key Metrics — Yuhan